Comparison of the clinical features and clinical course of antimitochondrial antibody‐positive and ‐negative primary biliary cirrhosis
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Reports from North America and Northern Europe have suggested that antimitochondrial antibody (AMA) negative primary biliary cirrhosis (PBC) is a distinct chronic cholestatic liver disease with high prevalence of serum non-organ-specific autoantibodies other than AMA. To evaluate if such a peculiar serum immunoreactivity is associated with clinically relevant characteristics, we reviewed our experience with 297 Italian patients who have had a clinical and histological diagnosis of PBC and were regularly followed-up at our Center from June 1974 to June 1994. AMA-negative and AMA-positive patients were compared in terms of biochemical and clinical features, and clinical outcome of the disease. At presentation, 30 of 297 patients (10%) tested negative for AMA by indirect immunofluorescence. Six of them tested positive for antimitochondrial M2 antibodies (AMA-M2) by immunoblotting analysis, therefore, diagnosis of AMA-negative PBC was made in 24 patients (8%). At the initial visit, AMA-negative and AMA-positive patients were similar in terms of biochemical and clinical features. Antinuclear and anti-smooth-muscle antibodies (ANA and ASMA) were more frequently positive in the AMA-negative patients (71% vs. 31%, and 37% vs. 9%; both P = .0002). Incidence of complications of cirrhosis and development of liver failure resulting in death or referral for liver transplantation did not differ significantly between the two populations. In conclusion, data from this historical cohort study suggest that the distinct serological features of AMA-negative PBC are not associated with substantial differences in the clinical spectrum or course of the disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although AMA-negative PBC patients are nearly identical to AMA-positive PBC patients, minor differences have been noted, including a higher prevalence of antinuclear and anti-smooth muscle antibodies and lower serum IgM levels.(111)(112)(113)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [113]
In the citing paper
“However, treatment response to UDCA appears similar in AMA-negative and AMA-positive PBC patients, and whether there are differences in clinical outcomes has not been resolved.(113,115)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [113]
Citations
Cites
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
Towbin, H., Staehelin, T., & Gordon, J. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.9.4350 · Cited by 53,385
Kaplan, M. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702263160907 · Cited by 1,959
Prognosis in primary biliary cirrhosis: Model for decision making
Dickson, R. E., Grambsch, P. M., Fleming, T. R., Fisher, L. D., & Langworthy, A. (1989) · Hepatology · doi:10.1002/hep.1840100102 · Cited by 816
(1959) · Postgraduate Medical Journal · doi:10.1136/pgmj.45.522.305-d · Cited by 497
Michieletti, P., Wanless, I. R., Katz, A., Scheuer, P. J., Yeaman, S. J., Bassendine, M. F., Palmer, J. M., & Heathcote, E. J. (1994) · Gut · doi:10.1136/gut.35.2.260 · Cited by 236
Autoimmune cholangiopathy: Part of the spectrum of autoimmune chronic active hepatitis
Ben-Ari, Z., Dhillon, A. P., & Sherlock, S. (1993) · Hepatology · doi:10.1002/hep.1840180103 · Cited by 218
Primary biliary cirrhosis: Paradigm or paradox for autoimmunity
Gershwin, M. E., & Mackay, I. R. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)80033-6 · Cited by 206
Antibodies to hepatitis C virus in autoimmune liver disease: evidence for geographical heterogeneity
Lenzi, M., Ballardini, G., Bianchi, F. B., Johnson, P. J., McFarlane, I. G., Smith, H. M., McFarlane, B. M., Bridger, C., Williams, R., & Vergani, D. (1991) · The Lancet · doi:10.1016/0140-6736(91)90418-o · Cited by 200
Antimitochondrial antibody-negative primary biliary cirrhosis.
Lacerda, M. A., Ludwig, J., Dickson, E. R., Jorgensen, R. A., & Lindor, K. (1995) · PubMed · Cited by 196
Cited by
Items 101–200 of 294
Variant forms of autoimmune hepatitis
Czaja, A. J. (1999) · Current Gastroenterology Reports · doi:10.1007/s11894-999-0089-0 · Cited by 41
Primary biliary cirrhosis: new perspectives in diagnosis and treatment
Prince, M. I., & Jones, D. E. J. (2000) · Postgraduate Medical Journal · doi:10.1136/pmj.76.894.199 · Cited by 37
“AMA are both the most specific and the most sensitive marker of disease presence and are found in over 95% of patients with PBC.”
Primary biliary cirrhosis in 2014
Flores, A. G., & Mayo, M. J. (2014) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000058 · Cited by 39
“An Italian cohort study with a 20-year followup reported similar incidence of complications of cirrhosis and development of liver failure, resulting in death or referral for liver transplantation in AMAnegative and AMA-positive patients [49].”
BackgroundD-penicillamine for primary biliary cirrhosis
Gong, Y., Klingenberg, S. L., & Gluud, C. N. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004789.pub2 · Cited by 38
Antimitochondrial Antibody–Negative Primary Biliary Cirrhosis
Mendes, F. D., & Lindor, K. D. (2008) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2008.02.006 · Cited by 36
Transitions between variant forms of primary biliary cirrhosis during long-term follow-up
Lindgren, S. C., Glaumann, H., Almer, S. H., Bergquist, A. M., Bjornsson, E. S., Broomé, U., Danielsson, Å., Lebrun, B., Prytz, H., & Olsson, R. (2009) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2008.12.011 · Cited by 35
Genes and (auto)immunity in primary biliary cirrhosis
Selmi, C. F., Invernizzi, P., Zuin, M. G., Podda, M., Seldin, M. F., & Gershwin, M. E. (2005) · Genes and Immunity · doi:10.1038/sj.gene.6364248 · Cited by 35
“101 similarly, patients with PBC lacking detectable AMA present clinical features similar to their AMA-positive counterparts”
BackgroundSelf-citationPrimary biliary cirrhosis: Evaluation with T2-weighted MR imaging and MR cholangiopancreatography
Haliloğlu, N. Ü., Erden, A., & Erden, İ. (2008) · European Journal of Radiology · doi:10.1016/j.ejrad.2007.11.003 · Cited by 35
Colchicine for primary biliary cirrhosis
Gong, Y., & Gluud, C. N. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004481.pub2 · Cited by 38
Anti-Mitochondrial Antibody–Negative Primary Biliary Cirrhosis
Selmi, C. F., Zuin, M. G., Bowlus, C. L., & Gershwin, M. E. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.11.008 · Cited by 35
Self-citationRole of Auto-Antibodies for the Diagnosis of Chronic Cholestatic Liver Diseases
Terjung, B., & Spengler, U. (2005) · Clinical Reviews in Allergy & Immunology · doi:10.1385/criai:28:2:115 · Cited by 38
Azathioprine for primary biliary cirrhosis
Gong, Y., Christensen, E., & Gluud, C. N. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006000.pub2 · Cited by 37
Hu, C., Deng, C., Song, G., Zhang, W., Zhang, S., Li, X., Li, P., Zhang, F., & Li, Y. (2011) · Digestive Diseases and Sciences · doi:10.1007/s10620-011-1756-1 · Cited by 33
Kobayashi, M., Kakuda, Y., Harada, K., Sato, Y., Sasaki, M., Ikeda, H., Terada, M., Mukai, M., Kaneko, S., & Nakanuma, Y. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i13.3597 · Cited by 34
Rheumatoid Arthritis and Primary Biliary Cirrhosis: Cause, Consequence, or Coincidence?
Smyk, D. S., Bogdanos, D. P., Mytilinaiou, M. G., Burroughs, A. K., & Rigopoulou, E. I. (2012) · Arthritis · doi:10.1155/2012/391567 · Cited by 37
Autoimmune Hepatitis Overlap Syndromes and Liver Pathology
Czaja, A. J., & Carpenter, H. A. (2017) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2017.01.008 · Cited by 35
“These patients may have an overlap syndrome with PBC, PSC, AMA-negative PBC, or small duct PSC.13,14 Forty-one percent of patients with AIH and concurrent inflammatory bowel disease have focal biliary strictures and dilations by cholangiography.32 Cholestatic laboratory changes or histologic findings of bile duct inju…”
BackgroundAssociation between rheumatoid arthritis and primary biliary cirrhosis
Caramella, C., Avouac, J., Sogni, P., Puéchal, X., Kahan, A., & Allanore, Y. (2007) · Joint Bone Spine · doi:10.1016/j.jbspin.2006.06.012 · Cited by 31
Role of autoantibodies in the clinical management of primary biliary cholangitis
Rigopoulou, E. I., & Bogdanos, D. P. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i12.1795 · Cited by 30
Animal Models of Primary Biliary Cirrhosis: Materials and Methods
Leung, P. S. C., Yang, G. X., Dhirapong, A., Tsuneyama, K., Ridgway, W. M., & Gershwin, M. E. (2012) · Methods in molecular biology · doi:10.1007/978-1-60761-720-4_14 · Cited by 33
The autoimmunity of primary biliary cirrhosis and the clonal selection theory
Selmi, C. F., Mackay, I. R., & Gershwin, M. E. (2010) · Immunology and Cell Biology · doi:10.1038/icb.2010.126 · Cited by 33
Chang, J., Go, S., Verhoeven, A. J., Beuers, U. H., & Elferink, R. P. J. O. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.09.022 · Cited by 32
Zhang, Q., Liu, Z., Wu, S., Duan, W., Chen, S., Ou, X., You, H., Kong, Y., & Jia, J. (2019) · Gastroenterology Research and Practice · doi:10.1155/2019/8959103 · Cited by 28
Primary biliary cirrhosis and autoimmune cholangiopathy
Vierling, J. M. (2004) · Clinics in Liver Disease · doi:10.1016/s1089-3261(03)00132-6 · Cited by 31
Variant syndromes of autoimmune hepatitis
Heathcote, J. (2002) · Clinics in Liver Disease · doi:10.1016/s1089-3261(02)00031-4 · Cited by 29
“UDCA has been used in some cases, and the biochemical response is similar to that in AMA-positive PBC [16–18].”
ResultJohn, B. V., Dahman, B. A., Deng, Y., Khakoo, N. S., Taddei, T. H., Kaplan, D. E., & Levy, C. (2021) · Liver International · doi:10.1111/liv.15079 · Cited by 29
Morisco, F., Pagliaro, L., Caporaso, N., Bianco, E., Sagliocca, L., Fargion, S. R., Smedile, A., Salvagnini, M., & Mele, A. (2008) · Digestive and Liver Disease · doi:10.1016/j.dld.2008.02.003 · Cited by 29
Humoral autoimmune response heterogeneity in the spectrum of primary biliary cirrhosis
Dellavance, A., Cançado, E. L. R., Abrantes‐Lemos, C. P., Harriz, M., Marvulle, V., & Andrade, L. E. C. (2012) · Hepatology International · doi:10.1007/s12072-012-9413-0 · Cited by 28
“Antimitochondria antibodies (AMAs) are detected in roughly 95 % of PBC patients, with a specificity of at least 98 % [3, 4].”
Serum autoantibodies: A road map for the clinical hepatologist
Meda, F., Zuin, M. G., Invernizzi, P., Vergani, D., & Selmi, C. F. (2008) · Autoimmunity · doi:10.1080/08916930701619227 · Cited by 30
“[14] Invernizzi P, Crosignani A, Battezzati PM, Covini G, De Valle”
BackgroundSelf-citationWęsierska‐Gądek, J., KLIMA, A., Komina, O., Ranftler, C., Invernizzi, P., & Penner, E. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1398.058 · Cited by 31
Self-citationAnti-mitochondrial autoantibodies
Fritzler, M. J., & Manns, M. P. (2002) · Clinical and Applied Immunology Reviews · doi:10.1016/s1529-1049(02)00058-2 · Cited by 30
Presentation and Diagnosis of Primary Biliary Cirrhosis in the 21st Century
Kumagi, T., & Onji, M. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.02.014 · Cited by 27
Screening for microRNA-based diagnostic markers in hepatic alveolar echinococcosis
Ren, B., Wang, H., Ren, L., Cairang, Y., Zhou, Y., Fan, H., & Lv, Y. (2019) · Medicine · doi:10.1097/md.0000000000017156 · Cited by 25
Ursodeoxycholic acid reduces CpG‐induced IgM production in patients with primary biliary cirrhosis
Kikuchi, K., Hsu, W., Hosoya, N., Moritoki, Y., Kajiyama, Y., Kawai, T., Takai, A., Hayami, E., Selmi, C. F., Gershwin, M. E., et al. (2008) · Hepatology Research · doi:10.1111/j.1872-034x.2008.00474.x · Cited by 25
Gisbert, J. P., Jones, E. A., Pajares, J. M., & Moreno‐Otero, R. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01381.x · Cited by 28
Antimitochondrial Antibody–Negative Primary Biliary Cholangitis
Chascsa, D. M. H., & Lindor, K. D. (2018) · Clinics in Liver Disease · doi:10.1016/j.cld.2018.03.009 · Cited by 28
Su, C., Hung, H.-H., Huo, T., Huang, Y., Li, C., Lin, H., Lee, P.-C., Lee, S., & Wu, J. (2008) · Liver International · doi:10.1111/j.1478-3231.2008.01715.x · Cited by 24
Comay, D., Cauch‐Dudek, K., Hemphill, D., Diamandis, E. P., Wanless, I. R., & Heathcote, E. J. (2000) · Digestive Diseases and Sciences · doi:10.1023/a:1005548126211 · Cited by 24
“It is unclear whether these patients represent a subset of PBC (1, 2), autoimmune hepatitis (AIH (3), or are a distinct entity unto themselves (4, 5).”
BackgroundMaking Sense of Autoantibodies in Cholestatic Liver Diseases
Marzorati, S., Invernizzi, P., & Lleo, A. (2016) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.08.003 · Cited by 23
“AMA titer does not correlate with severity or activity of the disease.(18) Despite the controversy reported in literature regarding the importance of its titration among PBC-affected patients,(19,20) AMA titer may differ by more than 200-fold, but in the single patient can remain stable over the years.”
BackgroundSelf-citationMethotrexate for primary biliary cirrhosis
Gong, Y., & Gluud, C. N. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004385.pub2 · Cited by 27
Yao, T. T., Qian, J., & Wang, G.-Q. (2020) · Medicina Clínica · doi:10.1016/j.medcli.2020.03.013 · Cited by 23
Xu, Q., Zhu, W., & Yin, Y. (2023) · Medicine · doi:10.1097/md.0000000000036039 · Cited by 23
The Importance of Autoantibody Detection in Primary Biliary Cirrhosis
Cançado, E. L. R., & Harriz, M. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00309 · Cited by 24
“There are other interesting models of the experimental induction of AMA reactivity and the development of PBC-like biliary duct lesions following the administration of xenobiotics in guinea-pigs and mice (2, 6).”
BackgroundUibo, R., Kisand, K. E., Yang, C., & Gershwin, M. E. (2012) · Apmis · doi:10.1111/j.1600-0463.2012.02914.x · Cited by 24
“stage of PBC [107]; however, it is detectable”
BackgroundCan Turner syndrome teach us about the pathogenesis of chronic cholestasis?
Milkiewicz, P., Heathcote, J., Jaeschke, H., Mullen, K. D., & Moradpour, D. (2004) · Hepatology · doi:10.1002/hep.20495 · Cited by 22
Serum Immunological Profile in Patients with Chronic Autoimmune Cholestasis
Romero‐Gómez, M., Wichmann, I., Crespo, J., Parés, A. R., Rodrigo, L., Álvarez, A. J., Diago, M., Pons‐Romero, F., Sánchez-Muñoz, D., Aguilar‐Reina, J., et al. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.40416.x · Cited by 24
“Serum that is AMA− by immunofluorescence (IIF) may, nevertheless, be AMA+ by ELISA or immunoblotting (9).”
BackgroundDubel, L., Farges, O., Courvalin, J., Sebagh, M., & Johanet, C. (1998) · Journal of Hepatology · doi:10.1016/s0168-8278(98)80220-1 · Cited by 22
Antilactoferrin Antibodies in Autoimmune Liver Diseases
Ohana, M., Okazaki, K., Hajiro, K., & Uchida, K. (1998) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1998.444_n.x · Cited by 22
“23 ), others suggest the unique findings of AIC; lower serum immunoglobulin M”
BackgroundTanaka, A., Ohira, H., Kikuchi, K., Nezu, S., Shibuya, A., Bianchi, I., Podda, M., Invernizzi, P., & Takikawa, H. (2011) · Tissue Antigens · doi:10.1111/j.1399-0039.2010.01600.x · Cited by 21
Self-citationCançado, G. G. L., Braga, M. H., Ferraz, M. L. G., Villela‐Nogueira, C. A., Terrabuio, D. R. B., Cançado, E. L. R., Nardelli, M. J., Faria, L. C., Gomes, N. M. D. F., Oliveira, E. M. G., et al. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-021-07122-y · Cited by 22
“As reported by other authors [22, 23, 29, 30], IgM levels were lower in AMA-negative patients with PBC when compared to their AMA-positive counterparts, but in contrast to other reports [21, 23, 29, 30], no increase in the frequency of either ANA or SMA was found in the former group of patients.”
BackgroundResultSelmi, C. F., Zuin, M. G., Biondi, M. L., Invernizzi, P., Battezzati, P. M., Bernini, M., Meda, F., Gershwin, M. E., & Podda, M. (2003) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2003.03160.x · Cited by 22
Self-citationAkisawa, N., Nishimori, I., Miyaji, E., Iwasaki, S., Maeda, T., Shimizu, H., Sato, N., & Onishi, S. (1999) · Journal of Gastroenterology · doi:10.1007/s005350050275 · Cited by 21
Cyclosporin A for primary biliary cirrhosis
Gong, Y., Christensen, E., & Gluud, C. N. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005526.pub2 · Cited by 22
Autoimmune Hepatitis: Clinical Manifestations and Diagnostic Criteria
McFarlane, I. G. (2001) · Canadian Journal of Gastroenterology · doi:10.1155/2001/279637 · Cited by 19
Primary biliary cirrhosis and liver transplantation
Akamatsu (2012) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2012.v1.2.66 · Cited by 26
Hair dyes as a risk for autoimmunity: from systemic lupus erythematosus to primary biliary cirrhosis
Smyk, D. S., Rigopoulou, E. I., Bizzaro, N., & Bogdanos, D. P. (2012) · Autoimmunity Highlights · doi:10.1007/s13317-011-0027-7 · Cited by 19
“Disease-specific ANA appear to be able to identify PBC patients with a more aggressive disease [36–38, 44, 48–59].”
BackgroundGraham, R. P., Smyrk, T. C., & Zhang, L. (2012) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31824b1dff · Cited by 18
Prevalence and significance of autoantibodies in patients with alcoholic liver disease
Lian, M., Hua, J., Li, S., & Qiu, D. (2013) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12057 · Cited by 19
REVIEW: Overlap Syndromes of Autoimmune Hepatitis: What Is Known So Far
Durazzo, M., Premoli, A., Fagoonee, S., & Pellicano, R. (2003) · Digestive Diseases and Sciences · doi:10.1023/a:1022597210629 · Cited by 18
Bargou, I., Mankaï, A., Jamaa, A., Jazia, I. B., Skandrani, K., Sfar, H., Baccouche, A., Ajmi, S., Letaief, A. O., Fabien, N., et al. (2007) · Pathologie Biologie · doi:10.1016/j.patbio.2007.05.001 · Cited by 17
The Enigma of Primary Biliary Cirrhosis
Selmi, C. F., Ichiki, Y., Invernizzi, P., Podda, M., & Gershwin, M. E. (2005) · Clinical Reviews in Allergy & Immunology · doi:10.1385/criai:28:2:073 · Cited by 17
Self-citationGenomic variants associated with primary biliary cirrhosis
Selmi, C. F., Torok, N. J., Affronti, A., & Gershwin, M. E. (2010) · Genome Medicine · doi:10.1186/gm126 · Cited by 17
“This connotes the condition known as AMAnega tive PBC or ‘autoimmune cholangiopathy’, now con sidered a nosological entity, practically identical to PBC apart from the serological profile [13,14].”
BackgroundBiliary Epithelial Apoptosis, Autophagy, and Senescence in Primary Biliary Cirrhosis
Sasaki, M., & Nakanuma, Y. (2010) · Hepatitis Research and Treatment · doi:10.1155/2010/205128 · Cited by 17
“A minor population of patients is AMA-negative, and these AMA-negative cases manifest similar histological features and disease progression [31].”
BackgroundAlric, L., Thébault, S., Selves, J., Péron, J., Mejdoubi, S., Fortenfant, F., & Vinel, J. (2007) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(07)89322-5 · Cited by 16
“Some recent studies have suggested a favorable response to UCDA alone [10, 21] or associated with prednisone [5] in patients with OS.”
BackgroundResultInfluentialInvernizzi, P., Bernuzzi, F., Lleò, A., Pozzoli, V., Bignotto, M., Zermiani, P., Crosignani, A. L., Battezzati, P. M., Zuin, M. G., Podda, M., et al. (2014) · Digestive and Liver Disease · doi:10.1016/j.dld.2013.11.008 · Cited by 15
Self-citationA case of Alagille syndrome presenting with chronic cholestasis in an adult
Kim, J., Yang, B., Paik, N., Choe, Y. H., & Paik, Y. (2017) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2016.0057 · Cited by 15
B cell depletion in treating primary biliary cirrhosis: Pros and cons
Yin, Y., & Zhang, X. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i30.3938 · Cited by 15
Jang, H. J., Kim, G. S., Eun, C. S., Kae, S. H., Jang, W. Y., & Lee, J. (2005) · Digestive Diseases and Sciences · doi:10.1007/s10620-005-3057-z · Cited by 15
“Nevertheless, 5–10% of patients with typical features of PBC do not have detectable AMA (8).”
BackgroundInfluentialMasuda, J., Omagari, K., Matsuo, I., Kinoshita, H., Sakimura, K., Hazama, H., Ohba, K., Isomoto, H., Murase, K., Murata, I., et al. (2001) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2001.02377.x · Cited by 15
Hosoda, H., Okawa‐Takatsuji, M., Tanaka, A., Uwatoko, S., Aotsuka, S.-I., Hasimoto, N., Ozaki, Y., & Ikeda, Y. (2004) · Clinica Chimica Acta · doi:10.1016/j.cccn.2003.10.015 · Cited by 15
Management of Primary Biliary Cirrhosis and Autoimmune Cholangitis
Angulo, P., & Lindor, K. D. (1998) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70011-8 · Cited by 14
New autoantibodies and autoantigens in autoimmune hepatitis
Bianchi, F. B., Muratori, P., & Muratori, L. (2002) · Clinics in Liver Disease · doi:10.1016/s1089-3261(02)00027-2 · Cited by 14
Autoimmune Markers in Primary Biliary Cholangitis
Shah, S. K., & Bowlus, C. L. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.07.002 · Cited by 15
Li, C.-H., Xu, P.-S., Wang, C., & Zou, G. (2005) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.08.009 · Cited by 12
Zhao, D., Liao, H.-Y., Liu, Y., Zhao, Y., Feng, X., & Yan, H. (2011) · Digestive Diseases and Sciences · doi:10.1007/s10620-011-1661-7 · Cited by 13
“Because serum positivity for AMA and/or AMA-M2 provided basis for screening patients with PBC in this study, patients who were AMAnegative, even if they met all the other criteria for the diagnosis of PBC, were potentially excluded [12].”
BackgroundCharacterization of M2 antibodies in asymptomatic Chinese population
Jiang, X., Zhong, R.-Q., Fan, X.-Y., Hu, Y., An, F., Sun, J.-W., & Kong, X.-T. (2003) · World Journal of Gastroenterology · doi:10.3748/wjg.v9.i9.2128 · Cited by 12
Primary Biliary Cirrhosis: Solving the Enigma
Giorgini, A., Selmi, C. F., Invernizzi, P., PODDA, M. U., Zuin, M. G., & Gershwin, M. E. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1361.060 · Cited by 14
Self-citationMiyakawa, H., Abe, K., Kitazawa, E., Kikuchi, K., Fujikawa, H., Matsushita, M., Kawaguchi, N., & Kako, M. (1999) · Autoimmunity · doi:10.3109/08916939908994755 · Cited by 12
Lazaridis, K. N., & Lindor, K. D. (1999) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-999-0051-0 · Cited by 12
Miyakawa, H. (2000) · Hepatology Research · doi:10.1016/s1386-6346(99)00079-0 · Cited by 11
Jiang, X., Zhong, R.-Q., Yu, S.-Q., Hu, Y., Li, W.-W., & Kong, X.-T. (2003) · World Journal of Gastroenterology · doi:10.3748/wjg.v9.i6.1352 · Cited by 11
Ueno, Y. (2001) · Hepatology Research · doi:10.1016/s1386-6346(00)00128-5 · Cited by 12
Role for mycobacterial infection in pathogenesis of primary biliary cirrhosis?
Smyk, D. S., Rigopoulou, E. I., Zen, Y., Abeles, R. D., Billinis, C., Parés, A. R., & Bogdanos, D. P. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i35.4855 · Cited by 10
Aibara, N., Ohyama, K., Nakamura, M., Nakamura, H., Tamai, M., Kishikawa, N., Kawakami, A., Tsukamoto, K., Nakashima, M., & Kuroda, N. (2021) · Clinical & Experimental Immunology · doi:10.1111/cei.13588 · Cited by 10
Hazama, H., Omagari, K., Masuda, J.-I., Kinoshita, H., Ohba, K., Sakimura, K., Matsuo, I., Isomoto, H., Murase, K., Murata, I., et al. (2000) · Journal of Clinical Laboratory Analysis · doi:10.1002/1098-2825(2000)14:5<208::aid-jcla2>3.0.co;2-6 · Cited by 10
Miyakawa, H. (1998) · Hepatology Research · doi:10.1016/s1386-6346(98)00054-0 · Cited by 10
Azathioprine for primary biliary cirrhosis
Gong, Y., Christensen, E., & Gluud, C. N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006000 · Cited by 10
Chlorambucil for patients with primary biliary cirrhosis
Li, W. X., Yan, X., Shi, C. R., & Zhang, A. P. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008714.pub2 · Cited by 9
Deng, C., Hu, C., Wang, L., Zhang, S., Li, P., Wu, Z., Chen, S., Zhang, F., & Li, Y. (2015) · Electrophoresis · doi:10.1002/elps.201400342 · Cited by 9
“1 in colour C© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.electrophoresis-journal.com reported significantly less bile duct damage around the portal areas in AMA-positive PBC patients compared with AMAnegative patients [8].”
BackgroundResultInfluentialThe latest research trends in primary biliary cholangitis: a bibliometric analysis
Zhao, Y., Yin, Z., Du, H., Huang, K., Zhang, F., & Chen, H. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00825-0 · Cited by 9
Clinical aspects of indirect immunofluorescence for autoimmune diseases
Ghanadan, A., Saghazadeh, A., Jahanzad, I., & Rezaei, N. (2015) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2015.1027152 · Cited by 9
“Therefore, there is a possible hypothesis and that is considering the DD of enrolled patients, as a significant difference in ANA and SMA positivity prevalence between AMA-positive and AMA-negative patients was found in a study population with a mean DD of 40 months [118], whereas this difference remained nonsignifica…”
BackgroundResultInfluentialHepatic Physiology and Pathophysiology
Mushlin, P. S., & Gelman, S. (2010) · Elsevier eBooks · doi:10.1016/b978-0-443-06959-8.00017-0 · Cited by 11
Primary Biliary Cirrhosis Associated with Painless Thyroiditis.
Sato, N., Ohira, H., Orikasa, H., SHINZAWA, J., Suzuki, T., Tojo, J., Miyata, M., Nishimaki, T., & Kasukawa, R. (1999) · Internal Medicine · doi:10.2169/internalmedicine.38.244 · Cited by 11
T-cell receptor polymorphism in primary biliary cirrhosis.
Selmi, C. F., Invernizzi, P., Tripputi, P., Battezzati, P. M., Bignotto, M., Zuin, M. G., Crosignani, A. L., & Podda, M. (2003) · PubMed · Cited by 9
Self-citationAutorinnen/Autoren, & Collaborators (2025) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2558-5204 · Cited by 10
Lindor, K. D., & Levy, C. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0881-3.00041-3 · Cited by 9
Li, C.-H., Xu, P.-S., Wang, C., Zhang, Y., & Zou, G. (2006) · Rheumatology International · doi:10.1007/s00296-005-0034-y · Cited by 8
“China E-mail: zouguolin@whu.edu.cn Tel.: +86-27-87645674 Fax: +86-27-68752560 Rheumatol Int (2006) 26: 697–703 DOI 10.1007/s00296-005-0034-y On the one hand, some AMA-negative patients show typical clinical, biochemical, and histological features similar to PBC [ 6 , 7]. On the other hand, AMA profiles do not predict…”
BackgroundInfluentialÖzaslan, E. (2009) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e328308bbaf · Cited by 8
[Guidelines on the diagnosis and management of primary biliary cholangitis (2021)].
(2021) · PubMed Central · doi:10.3760/cma.j.cn112138-20211112-00794 · Cited by 8
Selmi, C. F., & Gershwin, M. E. (2010) · Molecular pathology library · doi:10.1007/978-1-4419-7107-4_49 · Cited by 8
Immune-mediated bile duct injury: The case of primary biliary cirrhosis
Selmi, C. F., Affronti, A., Ferrari, L., & Invernizzi, P. (2010) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v1.i4.118 · Cited by 7
Self-citation
Metadata
- Authors
- Invernizzi, P., Crosignani, A., Battezzati, P. M., Covini, G., De Valle, G., Larghi, A., Zuin, M., & Podda, M.
- Affiliations
- Ospedale San Paolo (IT)
- Venue
- Hepatology
- Published
- 1997-05
- Volume
- 25
- Issue
- 5
- Pages
- 1090-1095
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1994218082
- Cited by
- 293
- References
- 18
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 4 · 2023: 5 · 2022: 5 · 2021: 7 · 2020: 7 · 2019: 4 · 2018: 7 · 2017: 8 · 2016: 5 · 2015: 10 · 2014: 11 · 2013: 6 · 2012: 18
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 6697 d)
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
- Keywords
- primary biliary cirrhosis, antimitochondrial antibodies, antinuclear antibodies, anti-smooth muscle antibodies, non-organ-specific autoantibodies, clinical course, cirrhosis complications, liver failure, liver transplantation, cholestatic liver disease
- MeSH terms
- Adult, Aged, Autoantibodies, Female, Humans, Liver Cirrhosis, Biliary, Male, Middle Aged, Mitochondria, Prognosis, Autoimmunity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.